Current Rating Overview
MarketsMOJO currently assigns Suraksha Diagnostic Ltd a 'Sell' rating, reflecting a cautious stance on the stock. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The Mojo Score stands at 36.0, indicating a below-average outlook compared to the broader healthcare services sector. The rating was revised on 05 February 2026, when the Mojo Score declined by 16 points from 52 to 36, signalling a shift in the stock’s risk and return profile.
Quality Assessment
As of 09 March 2026, Suraksha Diagnostic Ltd maintains a 'good' quality grade. This suggests that the company exhibits solid operational fundamentals and a stable business model within the healthcare services sector. Despite this, the quality rating alone is insufficient to offset concerns arising from other parameters. Investors should note that while the company’s core operations remain sound, recent financial results have shown signs of strain, particularly in profitability and debt management.
Valuation Perspective
The valuation grade for Suraksha Diagnostic Ltd is currently 'attractive'. This indicates that the stock is trading at a price level that may offer value relative to its earnings potential and asset base. However, an attractive valuation does not necessarily imply an immediate buying opportunity, especially when other factors such as financial health and technical trends are unfavourable. Investors should weigh this valuation against the broader context of the company’s performance and market conditions.
Financial Trend Analysis
The financial grade is rated 'negative' as of 09 March 2026. Recent quarterly results highlight several areas of concern. Operating profit to interest coverage has fallen to a low of 7.33 times, indicating tighter margins and increased financial risk. The debt-equity ratio has risen to 0.51 times, the highest recorded in recent periods, signalling a heavier reliance on debt financing. Interest expenses have also increased, with quarterly interest costs reaching ₹3.16 crores. These factors collectively point to deteriorating financial health, which weighs heavily on the stock’s outlook.
Technical Outlook
Technically, the stock is graded as 'bearish'. Price performance data as of 09 March 2026 shows a consistent downtrend across multiple time frames. The stock has declined by 3.08% in the last trading day, 4.49% over the past week, and 10.28% in the last month. Over the past six months, the stock has lost 14.04% of its value, and year-to-date returns stand at -3.34%. The one-year return is negative at -6.24%, underperforming the BSE500 index over the same period. This persistent weakness in price action reflects investor caution and a lack of positive momentum.
Performance Summary and Market Position
Suraksha Diagnostic Ltd’s recent financial results and market performance suggest challenges in both operational efficiency and market sentiment. The company’s operating profit to interest ratio and rising debt levels highlight financial pressures that could constrain future growth. Additionally, the stock’s underperformance relative to broader market indices over one, three, and six-month periods underscores the cautious stance investors have adopted.
For investors, the 'Sell' rating implies that the stock currently carries a higher risk profile with limited upside potential. While the valuation appears attractive, the negative financial trends and bearish technical signals suggest that the stock may face further downward pressure in the near term. Investors should carefully consider these factors before initiating or maintaining positions in Suraksha Diagnostic Ltd.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Investor Takeaway
Suraksha Diagnostic Ltd’s current 'Sell' rating by MarketsMOJO serves as a cautionary signal for investors. The rating reflects a combination of solid operational quality but offset by deteriorating financial health, bearish technical trends, and a valuation that, while attractive, does not compensate for the risks. Investors should monitor the company’s upcoming quarterly results and debt management strategies closely to assess any potential improvement in fundamentals.
Given the stock’s recent underperformance and financial challenges, a conservative approach is advisable. Investors seeking exposure to the healthcare services sector might consider alternative opportunities with stronger financial trends and technical momentum. Meanwhile, those holding Suraksha Diagnostic Ltd shares should evaluate their risk tolerance and investment horizon in light of the current rating and market conditions.
Market Context
The healthcare services sector continues to face headwinds from regulatory changes and competitive pressures. Suraksha Diagnostic Ltd’s microcap status adds an additional layer of volatility and liquidity risk. As of 09 March 2026, the broader market environment remains uncertain, with investors favouring companies demonstrating clear growth trajectories and robust financial health. This context further supports the cautious stance reflected in the 'Sell' rating.
Conclusion
In summary, Suraksha Diagnostic Ltd’s 'Sell' rating as of 05 February 2026, supported by a Mojo Score of 36.0, is grounded in a thorough analysis of current fundamentals and market performance as of 09 March 2026. While the company retains good operational quality and an attractive valuation, negative financial trends and bearish technical indicators suggest limited near-term upside. Investors should approach the stock with caution and consider the broader sector dynamics before making investment decisions.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
